Protagonist Therapeutics, Inc (PTGX) stock
PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)
Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –
Protagonist Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Protagonist Therapeutics's total assets was $885.54M at Jun 30, 2026. For fiscal 2025 it was $668.19M, down 10.3% from the year before. Over ten years it grew 46.3% a year on average. The highest annual figure on record is $744.73M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $668.19M | -10.3% |
| FY2024 | Dec 31, 2024 | $744.73M | +108.1% |
| FY2023 | Dec 31, 2023 | $357.95M | +44.4% |
| FY2022 | Dec 31, 2022 | $247.93M | -28.7% |
| FY2021 | Dec 31, 2021 | $347.70M | +7.2% |
| FY2020 | Dec 31, 2020 | $324.47M | +109.4% |
| FY2019 | Dec 31, 2019 | $154.92M | +11.1% |
| FY2018 | Dec 31, 2018 | $139.47M | -14.8% |
| FY2017 | Dec 31, 2017 | $163.73M | +74.2% |
| FY2016 | Dec 31, 2016 | $93.99M | +533.1% |
| FY2015 | Dec 31, 2015 | $14.85M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $885.54M | +23.3% |
| Q1 FY2026 | Mar 31, 2026 | $697.46M | -6.0% |
| Q4 FY2025 | Dec 31, 2025 | $668.19M | -10.3% |
| Q3 FY2025 | Sep 30, 2025 | $701.69M | +16.2% |
| Q2 FY2025 | Jun 30, 2025 | $718.01M | +16.8% |
| Q1 FY2025 | Mar 31, 2025 | $742.13M | +17.9% |
| Q4 FY2024 | Dec 31, 2024 | $744.73M | +108.1% |
| Q3 FY2024 | Sep 30, 2024 | $603.86M | +83.0% |
| Q2 FY2024 | Jun 30, 2024 | $614.63M | +91.8% |
| Q1 FY2024 | Mar 31, 2024 | $629.28M | +162.4% |
| Q4 FY2023 | Dec 31, 2023 | $357.95M | +44.4% |
| Q3 FY2023 | Sep 30, 2023 | $330.02M | +17.0% |
| Q2 FY2023 | Jun 30, 2023 | $320.47M | +3.2% |
| Q1 FY2023 | Mar 31, 2023 | $239.86M | -31.1% |
| Q4 FY2022 | Dec 31, 2022 | $247.93M | -28.7% |
| Q3 FY2022 | Sep 30, 2022 | $282.17M | -24.4% |
| Q2 FY2022 | Jun 30, 2022 | $310.51M | -23.2% |
| Q1 FY2022 | Mar 31, 2022 | $348.30M | +16.8% |
| Q4 FY2021 | Dec 31, 2021 | $347.70M | +7.2% |
| Q3 FY2021 | Sep 30, 2021 | $373.18M | +71.7% |
| Q2 FY2021 | Jun 30, 2021 | $404.23M | +79.7% |
| Q1 FY2021 | Mar 31, 2021 | $298.07M | +121.0% |
| Q4 FY2020 | Dec 31, 2020 | $324.47M | +109.4% |
| Q3 FY2020 | Sep 30, 2020 | $217.32M | +40.5% |
| Q2 FY2020 | Jun 30, 2020 | $224.98M | +51.9% |
| Q1 FY2020 | Mar 31, 2020 | $134.90M | +2.0% |
| Q4 FY2019 | Dec 31, 2019 | $154.92M | +11.1% |
| Q3 FY2019 | Sep 30, 2019 | $154.63M | +3.9% |
| Q2 FY2019 | Jun 30, 2019 | $148.11M | +7.7% |
| Q1 FY2019 | Mar 31, 2019 | $132.25M | -11.4% |
| Q4 FY2018 | Dec 31, 2018 | $139.47M | -14.8% |
| Q3 FY2018 | Sep 30, 2018 | $148.86M | +34.8% |
| Q2 FY2018 | Jun 30, 2018 | $137.47M | +95.1% |
| Q1 FY2018 | Mar 31, 2018 | $149.24M | +80.5% |
| Q4 FY2017 | Dec 31, 2017 | $163.73M | +74.2% |
| Q3 FY2017 | Sep 30, 2017 | $110.42M | +7.4% |
| Q2 FY2017 | Jun 30, 2017 | $70.48M | – |
| Q1 FY2017 | Mar 31, 2017 | $82.67M | – |
| Q4 FY2016 | Dec 31, 2016 | $93.99M | – |
| Q3 FY2016 | Sep 30, 2016 | $102.84M | – |
See a number that looks wrong?